إعلان
إعلان
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
4.21
USDبرعاية
+0.12
+2.81%
٠٢ يناير, ١٥:٥٨ UTC -5
مغلق
بعد الإغلاق
4.22
+0.02
+0.48%
تقارير أرباح RXRX
النسبة الإيجابية المفاجئة
RXRX تفوق 11 من 18 آخر التقديرات.
61%
التقرير التالي
بيانات التقرير القادم
٢٦ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$25.08M
/-$0.32
التغير الضمني من Q3 25 (Revenue/ EPS)
+384.59%
/-11.11%
التغير الضمني من Q4 24 (Revenue/ EPS)
+455.92%
/-39.62%
Recursion Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On ٠٥ نوفمبر ٢٠٢٥, RXRX reported earnings of -0.36 USD per share (EPS) for Q3 25, beating the estimate of -0.37 USD, resulting in a 4.61% surprise. Revenue reached 5.17 مليون, compared to an expected 17.32 مليون, with a -70.13% difference. The market reacted with a -0.80% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.32 USD, with revenue projected to reach 25.08 مليون USD, implying an decrease of -11.11% EPS, and increase of 384.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
٢٢ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.57
الفعلي
-$0.73
مفاجئة
-25.95%
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
What were Recursion Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Recursion Pharmaceuticals, Inc. Class A Common Stock reported EPS of -$0.36, beating estimates by 4.61%, and revenue of $5.17M, -70.13% below expectations.
How did the market react to Recursion Pharmaceuticals, Inc. Class A Common Stock's Q3 2025 earnings?
The stock price moved down -0.8%, changed from $5.00 before the earnings release to $4.96 the day after.
When is Recursion Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for ٢٦ فبراير ٢٠٢٦.
What are the forecasts for Recursion Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 10
analysts, Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of -$0.32 and revenue of $25.08M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان